the Clinical Research for Effectivity and Safety of Modified Hu-Lu-Ba-Wan in the treatment of Diabetic Kidney Disease

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Accord to the western diagnostic criteria for type 2 diabetes, or previous history of diabetes;
•2. Phase III DKD standard, the screening and early detection of urinary albumin/creatinine ratio (ACR) are accord with 30 ~ 300 mg/g;
•3. Syndrome differentiation of TCM syndrome type is kidney Yang deficiency;
•4. Normal serum creatine;
•5. After basic treatment, blood glucose was controlled in HbA1c < 8.5%, FPG < 9mmol/L, 2h postprandial blood glucose < 13.0mmol/L, and blood pressure was controlled in < 140/90mmhg.
•6. Male and female aged 25-70 years old;
•7. Sign informed consent form.

•1. Type 1 diabetes;
•2. Patients with severe primary cardiovascular and cerebrovascular diseases, liver and kidney dysfunction and hematopoietic system diseases;
•3. Infection, severe electrolyte disorder and other aggravating factors which are not controlled or the patients whose conditions are unstable;
•4. Excluding patients with a variety of primary and secondary renal diseases and diseases caused by hypertension, heart failure, acidosis and urinary tract infection with increased urinary protein;
•5. Mentally ill;
•6. Women who are pregnant or preparing for pregnancy or lactation;
•7. Patients who need long-term hormone therapy;
•8. Hypertension that is difficult to control, or secondary hypertension;
•9. The patients who the investigator expects poor compliance or inability to cooperate.

发起方

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology